Blood Clot News and Research

RSS

A Blood Clot is a mass of blood that forms when blood platelets, proteins, and cells stick together. When a blood clot is attached to the wall of a blood vessel, it is called a thrombus. When it moves through the bloodstream and blocks the flow of blood in another part of the body, it is called an embolus.

Trevo Retriever effectively removes blood clots in patients with stroke

Every 40 seconds, someone in the United States has a stroke, usually caused when a clot blocks an artery that supplies blood to the brain. Now the results of two multicenter studies published online in The Lancet on August 26 are giving physicians new innovative tools proven to better remove these clots that block blood flow.

26 Aug 2012

Women with heart attack symptoms receive lower quality of care than men

A new study published recently in the American Journal of Medicine, conducted by researchers in the Cardiac and Vascular Institute at NYU Langone Medical Center, found there was significantly lower quality of care and worse outcomes in women compared to men - particularly young women under age 35 who had heart attack symptoms.

23 Aug 2012

U of U researchers receive NIH grant to study cellular and molecular causes of blood clots

University of Utah Department of Medicine researchers have received $16 million from the National Institutes of Health (NIH) to set up a translational research center to study the cellular and molecular causes of blood clots, a serious threat to millions of people who have diabetes, are obese or have other metabolic disorders.

15 Aug 2012

FDA clears Stryker’s Trevo Pro Retriever to treat acute ischemic stroke

Stryker Neurovascular announced today that its Trevo Pro Retriever has been granted 510(k) market clearance by the U.S. Food and Drug Administration. The Trevo Pro Retriever is the next generation in clot removal technology from Stryker, utilizing proprietary Stentriever Technology for optimized clot integration and retrieval in patients experiencing acute ischemic stroke.

From Stryker 13 Aug 2012

Clinical trials to test safety of 3K3A-APC in patients with ischemic stroke

Clinical trials start this week for a stroke drug initially created by a team led by scientists at The Scripps Research Institute and the University of Southern California (USC), and further developed by biotech company ZZ Biotech.

9 Aug 2012

HCRI announces successful completion of randomization in DAPT Study

The Harvard Clinical Research Institute (HCRI) announced today the successful completion of randomization in the DAPT Study, with the total number of patients randomized exceeding the upper goal set for the Study.

8 Aug 2012

Anakinra can dramatically limit amount of brain damage in stroke patients

Scientists led by the President of The University of Manchester have demonstrated a drug which can dramatically limit the amount of brain damage in stroke patients.

From The University of Manchester 27 Jul 2012

LSDF announces $570,000 in awards to support commercialization of new health-related products

The Life Sciences Discovery Fund (LSDF) today announced nearly $570,000 in awards in its inaugural corporate grant program to support commercialization of new health and health-care products by four early-stage Washington-based companies.

25 Jul 2012

PAMAM G-3 actually prevents activation of the process that leads to thrombosis

A compound that mops up debris of damaged cells from the bloodstream may be the first in a new class of drugs designed to address one of medicine's most difficult challenges -- stopping the formation of blood clots without triggering equally threatening bleeding.

24 Jul 2012

Training EMS to interpret ECGs can expedite treatment for severe heart attacks

A new program that trains emergency medical service technicians (EMS) to read electrocardiograms so that they can evaluate patients with chest pain, and expedite treatment for the severe heart condition known as ST-segment elevation myocardial infarction (STEMI), a serious form of heart attack, has excellent results and should become the standard of care, according to two studies published in the current issue of the Canadian Journal of Cardiology.

21 Jul 2012

Smoking, hepatitis and liver transplantation: An interview with Dr Peter Ghali

We are very interested in hepatitis C as it is the most common indication for liver transplant in the Western world. The difficulty is that recurrence happens in the majority of patients within the first 2 to 7 years after transplant, and occasionally sooner.

18 Jul 2012

VHVI now offers new minimally invasive, catheter-based approach to dissolve pulmonary embolism

The Vanderbilt Heart and Vascular Institute (VHVI) now offers a minimally invasive, catheter-based approach to dissolving pulmonary embolism, a potentially life-threatening blood clot that form elsewhere in the body and travels into the lungs.

17 Jul 2012

Health risks of egg donation for young females

News is just breaking in India about Sushma Pandey, a 17-year-old young woman who died in 2010, two days after her third "egg donation." Her death is being attributed to the procedures used to extract eggs from healthy, desirable young females like Ms. Pandey. These eggs are often resold to affluent westerners for use in commercial production of their children. Her post-mortem report states she had "one abrasion, four contusions and a blood clot in the head, plus six injection marks" as well as "congestion in the ovaries and uterus."

14 Jul 2012

SLU professor to study how antithrombin might prevent premature death from heart disease

Alireza "Ray" Rezaie, Ph.D., professor of biochemistry and molecular biology at Saint Louis University School of Medicine, has received a $1.52 million NIH grant to study how the key blood clotting inhibitor antithrombin might be exploited to prevent premature death from heart disease.

12 Jul 2012

Neonate blood-brain barrier more intact than adults following stroke

The ability for substances to pass through the blood-brain barrier is increased after adult stroke, but not after neonatal stroke, according to a new study the UCSF that will be published July 11 in the Journal of Neuroscience.

11 Jul 2012

Hormone therapy still an acceptable treatment for menopausal symptoms: New joint statement

After 10 years of debate regarding the risks and benefits of hormone therapy, 15 top medical organizations have come together to issue a statement of agreement regarding the benefits of hormone therapy for symptomatic menopausal women. It was July 9, 2002, when the controversial, highly publicized Women's Health Initiative (WHI) published its assessment of hormone therapy for the prevention of chronic disease and concluded that risks exceeded benefits.

10 Jul 2012

JRD receives FDA priority review designation for XARELTO sNDAs to treat PE, DVT

Janssen Research & Development, LLC (Janssen R&D) announced today the U.S. Food and Drug Administration (FDA) has assigned a priority review designation to the supplemental New Drug Applications (sNDAs) filed on May 2, 2012 for XARELTO (rivaroxaban), an oral anticoagulant, seeking new indications to treat patients with deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent recurrent DVT and PE.

9 Jul 2012

Novel biomimetic strategy can dissolve blood clots before they cause serious damage or even death

Researchers at the Wyss Institute for Biologically Inspired Engineering at Harvard University have developed a novel biomimetic strategy that delivers life-saving nanotherapeutics directly to obstructed blood vessels, dissolving blood clots before they cause serious damage or even death.

6 Jul 2012

TMC receives NIH grant to evaluate pepducin in heart disease patients

Tufts Medical Center researchers are developing a first-of-its-kind drug to prevent deadly blood clots in heart disease patients, without the risk of serious bleeding associated with current medications. The National Heart, Lung, and Blood Institute of the National Institutes of Health has just awarded the team led by Athan Kuliopulos, MD, PhD, a $10 million grant to start testing a drug based on this novel technology.

4 Jul 2012

Study demonstrates effectiveness of combination therapy for breast cancer cells in vitro

A study conducted at Boston University School of Medicine (BUSM) demonstrates an effective combination therapy for breast cancer cells in vitro.

3 Jul 2012